Page last updated: 2024-09-05

sorafenib and melphalan

sorafenib has been researched along with melphalan in 6 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(melphalan)
Trials
(melphalan)
Recent Studies (post-2010) (melphalan)
6,5207305,2518,1341,3511,972

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chang, J; He, Y; Qi, C; Ren, H; Yang, Y; Zhang, D; Zhang, H; Zhao, M1
Dhiman, N; Jaitak, V; Kaur, K1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS1

Reviews

2 review(s) available for sorafenib and melphalan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies.
    Bioorganic & medicinal chemistry, 2020, 08-01, Volume: 28, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tetrazoles

2020

Trials

1 trial(s) available for sorafenib and melphalan

ArticleYear
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
    Annals of surgical oncology, 2012, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution

2012

Other Studies

3 other study(ies) available for sorafenib and melphalan

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
    European journal of medicinal chemistry, 2016, Aug-25, Volume: 119

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mechlorethamine; Mice; Pyrimidines

2016
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2010